The UK and US have secured a important trade agreement that will keep zero levies on UK medicine shipments being sold in the American market.
Key Provisions of the Deal
As part of the deal, the UK has pledged to boost expenditure on drugs through the NHS. This commitment secures that import taxes on these crucial products will be held at zero for a period of the next three years.
This development is in response to previous statements to significantly raise tariffs on branded pharmaceutical products, with figures discussed as high as double the cost.
"This agreement between the UK reinforces the international landscape for innovative medicines and establishes much-needed equity to U.S.–U.K. pharmaceutical trade," a statement noted.
Economic Impact
Drugs represent one of the UK's largest export categories to the America, which is easily the largest market for major companies like GSK and AstraZeneca.
Trade data indicate that in the year prior to last September, the UK exported pharmaceutical products valued at £11.1bn to the US. This value made up nearly one-fifth of British export trade in that period.
"This agreement protects work, increases investment and facilitates the UK to emerge as a worldwide center for medical research," a minister remarked.
Key NHS Changes
The deal involves several notable pledges from the UK:
- Revised Affordability Limit: The UK will raise the cost ceiling at which it judges new treatments to be too expensive by a quarter.
- Higher Drug Budget: There is a goal to raise overall health service expenditure on medicines from 0.3 percent of Gross Domestic Product to 0.6 percent over the next decade.
- Refund Ceiling: The amount pharmaceutical firms must refund to the NHS to stay within budget will be restricted at 15%. Previously, rebates exceeded 20%.
Recent Tensions
The deal comes amid a protracted row between the drug companies and the ministers over medicine costs and regulatory access.
These tensions were heightened by assertions that American customers were paying a premium for the same drugs than consumers in the Britain and the EU.
Recently, several significant pharmaceutical investments in the UK have been delayed or cancelled, while substantial expansions have been pledged toward US facilities.
The Science Minister publicly accepted that the NHS must spend more on drugs, noting that its expenditure on drugs had declined as a proportion of its total funding over the last ten years.
